Ligand Pharmaceuticals Inc LGND
We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. 10-K, Item 1
- Headquarters
- San Diego, CA
- CEO
- Todd C. Davis
- Next results
- around Feb 25, 2027
LGND among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
45 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 27, 2026 against Feb 28, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Cash from operations lower than net incomeCash from operations $49.4M vs net income $124.5M (FY ending Dec 31, 2025)
-
Receivables +55.3% ($38.4M to $59.6M) vs revenue +60.4% ($167.1M to $268.1M), -5.1 pts apart
9 more checks with nothing to note
-
Inventory -35.3% ($14.1M to $9.1M) vs revenue +60.4% ($167.1M to $268.1M), -95.7 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No longer listed: Valuation of Agenus partnered programs in Agenus acquisition. Same as last year: Impairment assessment of finite-lived intangibles; Financial royalty assets - recognition of income
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
45 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business. We have been able to grow our business over time by primarily acquiring royalties. However, we may not be able to identify and acquire a sufficient number of…
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
The manufacture and distribution of a biopharmaceutical product may be interrupted by regulatory agencies or supplier deficiencies. The manufacture of products generating our royalties is typically complex and is highly regulated. In particular, biopharmaceutical products are manufactured in specialized facilities that require the…
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
In addition, our collaboration partners may develop products, either alone or with others, that compete with the types of products they are developing with us (or that we are developing on our own). This would result in increased competition for our
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
We may undertake strategic acquisitions of operating biopharmaceutical companies or acquire securities of biopharmaceutical companies. Our failure to realize the expected benefits of such acquisitions could adversely affect our business, financial condition or results of operations.
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $196.2M | $131.3M | $167.1M | $268.1M |
| Net income | −$33.4M | $52.2M | −$4.0M | $124.5M |
| Operating cash flow | $137.8M | $49.6M | $97.0M | $49.4M |
| Free cash flow | $119.9M | $46.1M | $95.2M | $48.9M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$268.1M ▲ 60.4% in FY2025$124.5M in FY2025$48.9M ▼ 48.6% in FY2025
Recent filings
12 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 12, 2026KOZARICH JOHN W (Director) gave notice of a planned sale of 500 shares worth about $159K Form 144, approximate sale date Nov 11, 2026, under a 10b5-1 plan adopted Aug 12, 2026
-
Planned saleNov 12, 2026KOZARICH JOHN W (Director) gave notice of a planned sale of 500 shares worth about $162K Form 144, approximate sale date Nov 12, 2026, under a 10b5-1 plan adopted Aug 12, 2026
-
Planned saleNov 12, 2026MARTINE ZIMMERMANN (Director) gave notice of a planned sale of 2,000 shares worth about $636K Form 144, approximate sale date Nov 12, 2026
-
Planned saleNov 10, 2026Aryeh Jason (Director) gave notice of a planned sale of 3,000 shares worth about $960K Form 144, approximate sale date Nov 10, 2026
-
Planned saleNov 4, 2026Aryeh Jason (Director) gave notice of a planned sale of 282 shares worth about $90K Form 144, approximate sale date Nov 4, 2026
About the company
Ligand Pharmaceuticals Inc, San Diego, CA · from the 10-K filed Feb 27, 2026
We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure. Capital deployment and technology licensing are the primary drivers of our long-term growth.
- Headquarters
- San Diego, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq, OTC
- Fiscal year ends
- December 31
- Last results
- Oct 29, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LGND/export.csv") into a cell.